Tonix Pharmaceuticals Holding (TNXP) Asset Writedowns and Impairment (2024 - 2025)
Tonix Pharmaceuticals Holding (TNXP) posted Asset Writedowns and Impairment of -$649000.0 for Q4 2025, down 549.0% on a QoQ basis from -$100000.0 in Q3 2025.
Powered by 
Analysis
Tonix Pharmaceuticals Holding (TNXP) Asset Writedowns and Impairment (2024 - 2025) Analysis & Trends
Tonix Pharmaceuticals Holding has reported Asset Writedowns and Impairment for 2 years, with the latest figure at -$649000.0 in Q4 2025.
- On a quarterly basis, Asset Writedowns and Impairment changed N/A year-over-year to -$649000.0 in Q4 2025; TTM through Dec 2025 was -$449000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $669000.0, down 98.87% from the prior year.
- Asset Writedowns and Impairment was -$649000.0 for Q4 2025 at Tonix Pharmaceuticals Holding, down from -$100000.0 in the prior quarter.
- The five-year high for Asset Writedowns and Impairment was $59.0 million in Q2 2024, with the low at -$649000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn |
| 10 | Tonix Pharmaceuticals Holding | 220.65 Mn | 220.65 Mn | 12.84 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -649,000.00 |
| Sep 30, 2025 | -100,000.00 |
| Sep 30, 2024 | 300,000.00 |
| Jun 30, 2024 | 58.96 Mn |